[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseases Despite FDA approval nearly a decade ago, [...]

![[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US](http://koreabizwire.com/wp/wp-content/uploads/2024/01/Sandoz-Holzkirchen.png)








